Neurocrine Biosciences Inc vs iShares TIPS Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while iShares TIPS Bond ETF trades at $106.82. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TIP | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $112.20 |
52-Week Low | $123.10 | $106.77 |
Enterprise Value | $15.78B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TIP trades at $107.05 with minimal daily movement (+0.07%), showing stability amid broader market volatility. Technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The company has announced upcoming dividends totaling $1.84 per share for H2-2026, providing income appeal. Recent news highlights Treasury market volatility and inflation concerns that may impact bond-related equities.
The stock faces headwinds from bearish technical momentum and macroeconomic uncertainty around interest rates. Dividend payments offer some support, but limited fundamental data availability requires careful monitoring of upcoming financial disclosures for clearer valuation assessment.
Trailing returns across standard periods
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →